Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Ablynx : posts strong data on key drug, looks set for approval

share with twitter share with LinkedIn share with facebook
share via e-mail
10/03/2017 | 10:40am CET

The drug, caplacizumab, is a treatment for the rare condition acquired thrombotic thrombocytopenic purpura (aTTP) and the data revealed a 74% reduction in aTTP-related death, recurrence of aTTP or at least one major thromboembolic event during treatment with its drug.

Additionally, the proportion of individuals that experienced recurrence of aTTP during the study was found 67% lower compared to those receiving placebo treatment.

In a further bonus to the drug, the safety profile was found to be extremely strong, with no major differences found between the drug and placebo treatment. The exception being a higher level of bleed-related adverse events, 66.2% against 49.3% in placebo though they were noted to be mild or moderate in severity.

Dr Edwin Moses, CEO of Ablynx, commented: I am delighted by this outcome as it reinforces all our beliefs in the potential for caplacizumab to change the lives of patients affected by aTTP. This is a very important milestone for the company as it further validates our Nanobody platform and demonstrates our ability to discover and develop medicines that make a real difference for society. These results strengthen our resolve to obtain marketing approval as quickly as possible so that caplacizumab rapidly becomes available to patients suffering from this severe disease for which there is currently no approved drug available.

Ablynx has already applied for marketing authorisation the EMA and plans to file with the FDA in 2018. One of the major successes for the company is that the Belgium-based biotech has taken the treatment all the way through to Phase 3 by itself and now looks set to secure the potential peak sales of $400 million exclusively. It has already announced that it plans to market the drug with its own sales force.

European biotechs have, so far, lagged behind their counterparts across the Atlantic but this success will go some way to suggesting that it is possible within Europe to develop a company able to take treatments all the way through developmental stage to potential marketing authorisation.

(c) APS 2017. All Rights Reserved Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ABLYNX
12/12 ABLYNX : 12/12/2017 ablynx reports additional clinically important benefits of c..
12/12 ABLYNX : Reports additional clinically important benefits of caplacizumab from i..
12/07 ABLYNX : Will host a webcast to discuss additional data from its phase iii hercu..
11/29 ABLYNX : 29/11/2017 publication in accordance with article 14 of the belgian law..
11/29 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
11/21 ABLYNX : 21/11/2017 results from the phase iii hercules study of caplacizumab fo..
11/21 ABLYNX : Results from the phase iii hercules study of caplacizumab for the treat..
11/16 ABLYNX : 16/11/2017 ablynx announces results for the first nine months of 2017 a..
11/16 ABLYNX : Announces results for the first nine months of 2017 and a year-to-date ..
11/15 ABLYNX : 15/11/2017 publication in accordance with article 14 of the belgian law..
More news
News from SeekingAlpha
12/07 Ablynx to update on Phase 3 study of caplacizumab December 12
11/16 Ablynx NV reports 9M results
10/18 YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
10/17 Ablynx prices $175M U.S. IPO at $20.95
10/04 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 4, 2017
Financials (€)
Sales 2017 64,7 M
EBIT 2017 -56,3 M
Net income 2017 -67,9 M
Finance 2017 203 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 20,5x
EV / Sales 2018 23,7x
Capitalization 1 528 M
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 22,9 €
Spread / Average Target 12%
EPS Revisions
Edwin Moses Chief Executive Officer & Executive Director
Peter John Fellner Chairman
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
Robert K. Zeldin Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX86.59%1 794
CELLTRION, INC.--.--%23 085
LONZA GROUP57.44%19 299